Aspire Biopharma Holdings Inc risk profile
84 Acute at or past the historical limit
Measured 21 October 2026 from ASBP's filed statements. Recomputed nightly.
84 (Acute), driven by Leverage and coverage at 100, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | Reads pct_below_52w_high, volatility_1y_pct and avg_turnover_90d_usd. No reading is stored for this company. | |||
| Operating pressure | Reads cost_of_revenue, operating_expense, operating_income and revenue. No reading is stored for this company. | |||
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | 100 | Acute | Stable | Net debt to EBITDA |
| Competitive position | 69 | Stretched | Stable | Operating-margin gap against peers — -312,015.9 percentage points |
| Concentration | 99 | Acute | Stable | Geographic concentration — 9,843 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Consumer Cyclical companies with a risk reading
Amazon.com Inc 48Tesla Inc 46Home Depot Inc 52Alibaba Group Holding Ltd 69Toyota Motor Corporation 38LVMH Moët Hennessy - Louis Vuitton Société Européenne 45LVMH Moet Hennessy Louis Vuitton SE 39McDonald`s Corp 30TJX Companies Inc 43Hermes International SCA 22HERMES INTL 25Fast Retailing Co., Ltd. 29
Financials, valuation and price history for Aspire Biopharma Holdings Inc